Shots:

• The approval is based on P-III ASPECT-NP study results assessing Zerbaxa (3gm- IV every 8hrs.) vs meropenem (1gm- IV- every 8hrs.) in 726 patients with HABP/VABP on mechanical ventilation aged ≥18yrs.
• The P-III ASPECT-NP study results demonstrated that Zerbaxa is superior to meropenem for 28-day all-cause mortality (24% vs 25.3%)- clinical response at Test-of-Cure (54.4% vs 53.3%)
• Zerbaxa is a combination therapy of anti-bacterial & beta-lactamase inhibitor- act by reducing the development of drug-resistant bacteria and has received FDA’s Priority Review designation for preventing infection by susceptible Gram-negative microorganisms

Ref: Merck | Image: Merck